RIGL — Rigel Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $344.47m
- $326.83m
- $179.28m
- 76
- 53
- 93
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.32 | ||
| PEG Ratio (f) | 0.76 | ||
| EPS Growth (f) | 25.28% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 104.77 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 11.09 | ||
| Price to Sales | 1.92 | ||
| EV to EBITDA | 12.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 24.03% | ||
| Return on Equity | n/a | ||
| Operating Margin | 13.49% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 108.62 | 149.24 | 120.24 | 116.88 | 179.28 | 197.79 | 228.79 | 24.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | +5.1 | +66.51 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Directors
- Gary Lyons NEC (69)
- Raul Rodriguez PRE (60)
- Dean Schorno CFO (58)
- Dolly Vance EVP (56)
- Wolfgang Dummer EVP (55)
- David Santos EVP (58)
- Kamil Ali-Jackson DRC (62)
- Alison Hannah DRC (59)
- Bradford Goodwin IND (66)
- Keith Katkin IND (49)
- Brian Kotzin IND (72)
- Gregg Lapointe IND (62)
- Walter Moos IND (66)
- Jane Wasman IND (64)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 14th, 1996
- Public Since
- November 29th, 2000
- No. of Shareholders
- 28
- No. of Employees
- 162
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 17,866,891
- Address
- 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.rigel.com/
- Phone
- +1 6506241100
- Auditors
- Ernst & Young LLP
Upcoming Events for RIGL
Rigel Pharmaceuticals Inc Annual Shareholders Meeting
Rigel Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Rigel Pharmaceuticals Inc Earnings Release
Similar to RIGL
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Rigel Pharmaceuticals share price?
As of Today at 22:56 UTC, shares in Rigel Pharmaceuticals are trading at $19.28. This share price information is delayed by 15 minutes.
How has the Rigel Pharmaceuticals share price performed this year?
Shares in Rigel Pharmaceuticals last closed at $19.28 and the price had moved by +75.27% over the past 365 days. In terms of relative price strength the Rigel Pharmaceuticals share price has outperformed the S&P500 Index by +61.78% over the past year.
What are the analyst and broker recommendations for Rigel Pharmaceuticals?
The overall consensus recommendation for Rigel Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Rigel Pharmaceuticals dividend yield?
Rigel Pharmaceuticals does not currently pay a dividend.
Does Rigel Pharmaceuticals pay a dividend?
Rigel Pharmaceuticals does not currently pay a dividend.
When does Rigel Pharmaceuticals next pay dividends?
Rigel Pharmaceuticals does not currently pay a dividend.
How do I buy Rigel Pharmaceuticals shares?
To buy shares in Rigel Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rigel Pharmaceuticals?
As of the previous close price of $19.28, shares in Rigel Pharmaceuticals had a market capitalisation of $344.47m.
Where are Rigel Pharmaceuticals shares listed?
Here are the trading details for Rigel Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RIGL
What kind of share is Rigel Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Rigel Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rigel Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Rigel Pharmaceuticals is $33.67. That is 74.64% above the last closing price of $19.28.
Analysts covering Rigel Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $1.04 for the next financial year.
Find out moreWhat is the trend in the Rigel Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rigel Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +43.51%.
As of the last closing price of $19.28, shares in Rigel Pharmaceuticals were trading +11.4% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rigel Pharmaceuticals PE Ratio?
The Rigel Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 15.32. The shares last closed at $19.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rigel Pharmaceuticals?
Rigel Pharmaceuticals' management team is headed by:
- Gary Lyons - NEC
- Raul Rodriguez - PRE
- Dean Schorno - CFO
- Dolly Vance - EVP
- Wolfgang Dummer - EVP
- David Santos - EVP
- Kamil Ali-Jackson - DRC
- Alison Hannah - DRC
- Bradford Goodwin - IND
- Keith Katkin - IND
- Brian Kotzin - IND
- Gregg Lapointe - IND
- Walter Moos - IND
- Jane Wasman - IND